Tracking every rollback, reversal, and overreach — and the path back to the America we know.
The Trump administration announced 100% tariffs on patented drugs to force pharmaceutical companies into pricing negotiations and shift manufacturing to America. This action leverages tariff threats to compel drugmakers into 'most-favored nation' pricing deals. The policy directly impacts drug prices and availability for American consumers while pressuring companies to relocate production domestically.
President Trump signed Executive Order 14273 on April 15, 2025, implementing measures aimed at lowering prescription drug prices for American consumers. The order directs federal agencies to reduce pharmaceutical costs through regulatory reform and market mechanisms. This action is intended to decrease out-of-pocket medication expenses for Medicare, Medicaid, and privately insured Americans.
President Trump signed Executive Order 14200 on February 5, 2025, amending duties addressing the synthetic opioid supply chain from the People's Republic of China. The order modifies tariff and trade policies targeting Chinese opioid precursors and finished products. This directly impacts American pharmaceutical supply chains, drug prices, and law enforcement efforts against fentanyl trafficking.
Executive Order 13939 was signed on July 24, 2020, directing the Department of Health and Human Services to issue a safe harbor rule removing anti-kickback protections for rebates in drug pricing negotiations. The order aimed to increase price transparency by allowing pharmaceutical manufacturers, pharmacy benefit managers, and health plans to negotiate rebates directly. The confirmed effect was that HHS issued a proposed rule in January 2021 to modify anti-kickback statute safe harbors, though implementation faced legal challenges and the rule's real-world impact on patient drug prices remained subject to ongoing litigation.
On July 24, 2020, President Trump signed Executive Order 13947 directing federal agencies to take steps to lower drug prices and increase price transparency. The order instructed the Department of Health and Human Services to allow states to import prescription drugs from Canada, permit Medicare to negotiate drug prices directly, and require drug manufacturers to disclose prices in direct-to-consumer advertising. Implementation faced legal challenges and delays; some provisions did not take effect during the Trump administration.